| Literature DB >> 26159216 |
Yeon Joo Jung1, Kyung-Chul Kim2, Jun-Young Heo2, Kaipeng Jing2,3, Kyung Eun Lee1, Jun Seok Hwang1, Kyu Lim2, Deog-Yeon Jo4, Jae Pyoung Ahn5, Jin-Man Kim6, Kang Moo Huh7, Jong-Il Park2,3.
Abstract
hBMSCs are multipotent cells that are useful for tissue regeneration to treat degenerative diseases and others for their differentiation ability into chondrocytes, osteoblasts, adipocytes, hepatocytes and neuronal cells. In this study, biodegradable elastic hydrogels consisting of hydrophilic poly(ethylene glycol) (PEG) and hydrophobic poly(ε-caprolactone) (PCL) scaffolds were evaluated for tissue engineering because of its biocompatibility and the ability to control the release of bioactive peptides. The primary cultured cells from human bone marrow are confirmed as hBMSC by immunohistochemical analysis. Mesenchymal stem cell markers (collagen type I, fibronectin, CD54, integrin1β, and Hu protein) were shown to be positive, while hematopoietic stem cell markers (CD14 and CD45) were shown to be negative. Three different hydrogel scaffolds with different block compositions (PEG:PCL=6:14 and 14:6 by weight) were fabricated using the salt leaching method. The hBMSCs were expanded, seeded on the scaffolds, and cultured up to 8 days under static conditions in Iscove's Modified Dulbecco's Media (IMDM). The growth of MSCs cultured on the hydrogel with PEG/PCL= 6/14 was faster than that of the others. In addition, the morphology of MSCs seemed to be normal and no cytotoxicity was found. The coating of the vascular endothelial growth factor (VEGF) containing scaffold with Matrigel slowed down the release of VEGF in vitro and promoted the angiogenesis when transplanted into BALB/c nude mice. These results suggest that hBMSCs can be supported by a biode gradable hydrogel scaffold for effective cell growth, and enhance the angiogenesis by Matrigel coating.Entities:
Keywords: VEGF; angiogenesis; controlled release; hBMSC; hydrogel
Mesh:
Substances:
Year: 2015 PMID: 26159216 PMCID: PMC4507034 DOI: 10.14348/molcells.2015.0142
Source DB: PubMed Journal: Mol Cells ISSN: 1016-8478 Impact factor: 5.034
Fig. 1.Characterization of mesenchymal stem cells from human bone marrow. Cells were stained for specific mesenchymal stem cell markers with corresponding antibodies and analyzed using a confocal microscope (× 600). Positive markers: Integrin B, collagen type I, fibronectin, CD-54. Negative markers: CD-45, CD-14. Culture media: IMDM/20% FBS, 2 mM Glutamine (passage 3). The right figures of two upper lanes are merge of left two figures.
Fig. 2.Viability of hBMSC on the plate type PEG:PCL scaffolds. (A) Cells were seeded on three kinds of PEG:PCL plate type scaffolds and incubated for 2 days or 8 days. Cell viability was determined by MTT assay. (B) Low (left) and high (right) magnification of hBMSCs on PEG:PCL (6:14) scaffolds after 2 days of culture were examined using H&E staining.
Fig. 3.Biodegradation rates of porous PEG:PCL polymer in vitro and in vivo. (A, B) After incubating in IMDM with 10% FBS for 2 days and 10 weeks, scaffolds were analyzed using SEM (× 500). (B–E) Scaffolds were transplanted into the back flank of BALB/c nude mice subcutaneously for 1, 2, 4 weeks. Removed scaffolds were examined under a light microscope (× 400).
Fig. 4.Influence of Matrigel coating on the release of VEGF from porous PEG:PCL(6:14) scaffolds. Porous scaffolds scaffolds containing VEGF was coated with Matrigel were placed in PBS. Released VEGF was assayed by ELISA.
Fig. 5.Cell recruitment at early phase of transplantation by Matrigel-coated scaffolds containing VEGF. Combinatorial scaffolds were implanted into the back flank of BLAB/c nude mice subcutaneously. Immunohistochemistry analysis against CD-31 was performed after 1 week. (A) Scaffolds only, (B) Matrigel coated scaffolds, (C) Scaffolds with VEGF, and (D) VEGF containing scaffolds coated by Matrigel.
Fig. 6.Angiogenic effects of Matrigel-coated scaffolds containing VEGF. Combinatorial scaffolds were implanted into the back flank of BLAB/c nude mice subcutaneously. Immunohistochemistry analysis against CD-31 was performed after 4 weeks. (A) Scaffolds only, (B) Matrigel coated scaffolds, (C) Scaffolds with VEGF, and (D) VEGF containing scaffolds coated with Matrigel. (E) Statistic analysis for CD-31 positive vessels (*p < 0.05).